DBV Technologies Release: Presentation And Publication Of Research At American Academy of Allergy, Asthma and Immunology (AAAAI) Demonstrates EPIT(TM)'S Ability To Rebalance The Immune System And Induce A Disease-Modifying Effect

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BAGNEUX, France, March 4, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of ViaskinĀ®, a new paradigm for the treatment of allergies, today announced that further preclinical data supporting Epicutaneous Immunotherapy's (EPITTM) immune-modulating long-lasting and protective effect were presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) and recently published in the Journal of Allergy and Clinical Immunology ("State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous"; Stacie M. Jones, A. Wesley Burks, and Christophe Dupont; JACI, February 2014, Volume 133, Number 2).

Help employers find you! Check out all the jobs and post your resume.

Back to news